Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Pomalidomide in Relapsed/Refractory Multiple Myeloma
NCT07757412Phase 2Not yet recruiting
- Sponsor
- University Hospital Odense
- Start
- Sep 2026
- Primary completion
- Jan 2029
- Countries
- 4
01
Overview
A Phase 2 trial of teclistamab in multiple myeloma (MM), sponsored by University Hospital Odense. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07757412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757412.